Showing results (51-60 of 99) with videos related to

Sort By:
Pageof 10
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 10, 2010
A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysisAshok Seth, Patrick W Serruys, Alexandra Lansky, et al.
The Journal of Clinical Endocrinology and Metabolism|January 15, 2002
Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERsMaro R I Williams, Shanhong Ling, Tye Dawood, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 22, 2012
Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trialsElvin Kedhi, Gregg W Stone, Dean J Kereiakes, et al.
JACC. Cardiovascular Interventions|June 23, 2012
Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States studySrihari S Naidu, Mitchell W Krucoff, David R Rutledge, et al.
JACC. Cardiovascular Interventions|February 5, 2010
3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions)Scot Garg, Patrick Serruys, Yoshinobu Onuma, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|November 21, 2016
One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trialsJosé de Ribamar Costa, Alexandre Abizaid, Antonio L Bartorelli, et al.
American Heart Journal|November 10, 2012
ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study designRoberto Diletti, Patrick W Serruys, Vasim Farooq, et al.
JACC. Cardiovascular Interventions|November 19, 2013
5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions)Hemal Gada, Ajay J Kirtane, William Newman, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 15, 2010
In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trialTakayuki Okamura, Scot Garg, Juan Luis Gutiérrez-Chico, et al.
JACC. Cardiovascular Interventions|January 15, 2011
Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trialsDean J Kereiakes, Krishnankutty Sudhir, James B Hermiller, et al.
Pageof 10